Australian Full Federal Court Upholds Basic Lipitor Patent, Preventing Launch of Generic Ranbaxy Product
The court found that a proposed Ranbaxy generic product would infringe Pfizer's basic Lipitor patent (AU 601,981). A second patent covering the calcium salt of atorvastatin (AU 628,198), which expires in September 2012, was ruled invalid by the court. Pfizer has the opportunity to appeal that ruling.
The Australian decision will not impact ongoing Lipitor patent actions in other countries, including the United States. Pfizer said it will continue to vigorously defend against challenges to its intellectual property, noting that patents provide the necessary incentive to invest in new and life-saving medicines that benefit millions of patients globally.
Vanessa Aristide, 212-733-3784
Suzanne Harnett, 212-733-8009
Posted: May 2008
Recommended for you